| Both sides previous revisionPrevious revisionNext revision | Previous revision |
| start [2024/03/25 12:31] – len | start [2024/04/23 10:09] (current) – [Patents invalidated by Obviousness-Type Double Patenting (posted 01/23/24)] len |
|---|
| > It is undisputed off-line batch processing was conventional at the time of invention. The ’443 patent does not suggest the claimed invention uses off-line batch processing in an unconventional manner. The claimed invention uses conventional off-line batch processing to more efficiently implement the abstract idea of identifying advertisements based on search results. This is insufficient to transform claim 13 into patent-eligible subject matter. We have repeatedly held "claiming the improved speed or efficiency inherent with applying the abstract idea on a computer [does not] provide a sufficient inventive concept." | > It is undisputed off-line batch processing was conventional at the time of invention. The ’443 patent does not suggest the claimed invention uses off-line batch processing in an unconventional manner. The claimed invention uses conventional off-line batch processing to more efficiently implement the abstract idea of identifying advertisements based on search results. This is insufficient to transform claim 13 into patent-eligible subject matter. We have repeatedly held "claiming the improved speed or efficiency inherent with applying the abstract idea on a computer [does not] provide a sufficient inventive concept." |
| </div> | </div> |
| | |
| | * [[lex>library/detail.aspx?g=7fd636d5-c138-48fb-a131-9caeec77cb17|Summary]] |
| |
| |
| The Federal Circuit rejected Cellect’s attempt to argue that ODP should not apply to patent term adjustments under 35 U.S.C. § 154(b)(2)(B) for the same reason that they don't apply to patent term extensions under 35 U.S.C. § 156. ((35 U.S.C. § 156 allows an applicant/patentee to extend a patent that covers a product whose market introduction is deleted due to the FDA approval process.)) The Court also addressed Cellect's other arguments and rejected each in turn, finding that the patents are invalid under obviousness-type double patenting and therefore unenforceable. | The Federal Circuit rejected Cellect’s attempt to argue that ODP should not apply to patent term adjustments under 35 U.S.C. § 154(b)(2)(B) for the same reason that they don't apply to patent term extensions under 35 U.S.C. § 156. ((35 U.S.C. § 156 allows an applicant/patentee to extend a patent that covers a product whose market introduction is deleted due to the FDA approval process.)) The Court also addressed Cellect's other arguments and rejected each in turn, finding that the patents are invalid under obviousness-type double patenting and therefore unenforceable. |
| |
| :!: **UPDATE:** ON November 13, 2023, Cellect filed a petition for //en banc// rehearing, which has attracted several amici briefs, which raise some interesting points. | On November 13, 2023, Cellect filed a petition for //en banc// rehearing, which has attracted several amici briefs, which raise some interesting points. On January 19, 2024, the request for rehearing was {{ :legal:double_patenting:cellect_en_banc_denial.pdf |denied}}. |
| |
| * [[po>patent/2023/11/adjustment-rehearing-patenting.html|Summary, analysis, and comments]] | * [[po>patent/2023/11/adjustment-rehearing-patenting.html|Summary, analysis, and comments]] |
| |
| * [[lex>library/detail.aspx?g=5e0577b2-c37d-4b6b-9e72-133bcfda0c12|Summary and analysis]] 8-) | * [[lex>library/detail.aspx?g=5e0577b2-c37d-4b6b-9e72-133bcfda0c12|Summary and analysis]] 8-) |
| * [[akin>https://www.akingump.com/en/insights/blogs/ip-newsflash/in-wake-of-in-re-cellect-district-court-interprets-safe-harbor-statute-and-finds-patent-not-invalid-for-obviousness-type-double-patenting|Discussion of Allergan]]. | |
| * [[fr>insights/thought-leadership/blogs/district-of-delaware-finds-allergan-patents-invalid-for-lack-of-written-description-and-obviousness-type-double-patenting-in-allergan-v-msn-labs/|Discussion of Allergan vis a vis Cellect]] | * [[fr>insights/thought-leadership/blogs/district-of-delaware-finds-allergan-patents-invalid-for-lack-of-written-description-and-obviousness-type-double-patenting-in-allergan-v-msn-labs/|Discussion of Allergan vis a vis Cellect]] |
| | * [[fcb>2023/06/19/argument-recap-in-re-cellect-llc-cellect-ii/|Summary of arguments]] 8-) |
| |
| |